Joseph Sanfrancesco1, Jesse K McKenney, Mariah Z Leivo, Sounak Gupta, Paul Elson, Donna E Hansel. 1. From the Pathology and Laboratory Medicine Institute (Drs Sanfrancesco and McKenney) and the Quantitative Health Sciences Institute (Dr Elson), Cleveland Clinic, Cleveland, Ohio; and the Department of Pathology, University of California at San Diego, La Jolla (Drs Leivo, Gupta, and Hansel). Dr Sanfrancesco is now with the Department of Pathology and Immunology, Washington University, St Louis, Missouri.
Abstract
CONTEXT: -Sarcomatoid urothelial carcinoma (UCa) is a rare but aggressive variant of bladder cancer that can show diagnostic challenges even using ancillary techniques. OBJECTIVE: -To examine immunohistochemical markers in the context of sarcomatoid UCa, including those associated with epithelial-to-mesenchymal transition. DESIGN: -Twenty-eight cases of sarcomatoid UCa were rereviewed. Clinical outcomes were obtained through database search. Immunohistochemistry for clinical and epithelial-to-mesenchymal transition markers was performed. RESULTS: -All patients had biopsy-proven invasive UCa; 61% (17 of 28) had sarcomatoid UCa at initial diagnosis. A recognizable epithelial component(s) was present in 17 lesions. The sarcomatoid component accounted for 65% of the lesion (average), with heterologous elements present in 3 of 28 cases (11%). The morphologic spectrum of the sarcomatoid element included spindled not otherwise specified, myxoid, pseudoangiosarcomatous, and malignant fibrous histiocytoma-like undifferentiated features. The sarcomatoid component was immunoreactive for pancytokeratin (22 of 26; 85%), p63 (20 of 26; 77%), cytokeratin 903 (17 of 26; 65%), cytokeratin 7 (16 of 26; 62%), GATA3 (16 of 26; 62%), and cytokeratin 5/6 (16 of 26; 62%). STAT-6, CD31, CD34, and HMB45 were all nonreactive, whereas smooth muscle actin often showed at least focal immunoreactivity (22 of 26; 85%). Epithelial-to-mesenchymal transition markers were frequently expressed, including vimentin (26 of 26; 100%), FoxC2 (26 of 26; 100%), SNAIL (23 of 26; 88.5%), and ZEB1 (18 of 26; 69.2%). Follow-up was available for 24 patients (median, 7 months). Sixteen of 28 patients (57%) died of disease (overall mean survival, 9.1 months). The presence of myxoid or chordoid features was associated with reduced survival (P < .05). CONCLUSIONS: -Sarcomatoid UCa is an aggressive form of UCa that frequently expresses epithelial-to-mesenchymal transition markers, suggesting a possible mechanism associated with aggressive tumor behavior.
CONTEXT: -Sarcomatoid urothelial carcinoma (UCa) is a rare but aggressive variant of bladder cancer that can show diagnostic challenges even using ancillary techniques. OBJECTIVE: -To examine immunohistochemical markers in the context of sarcomatoid UCa, including those associated with epithelial-to-mesenchymal transition. DESIGN: -Twenty-eight cases of sarcomatoid UCa were rereviewed. Clinical outcomes were obtained through database search. Immunohistochemistry for clinical and epithelial-to-mesenchymal transition markers was performed. RESULTS: -All patients had biopsy-proven invasive UCa; 61% (17 of 28) had sarcomatoid UCa at initial diagnosis. A recognizable epithelial component(s) was present in 17 lesions. The sarcomatoid component accounted for 65% of the lesion (average), with heterologous elements present in 3 of 28 cases (11%). The morphologic spectrum of the sarcomatoid element included spindled not otherwise specified, myxoid, pseudoangiosarcomatous, and malignant fibrous histiocytoma-like undifferentiated features. The sarcomatoid component was immunoreactive for pancytokeratin (22 of 26; 85%), p63 (20 of 26; 77%), cytokeratin 903 (17 of 26; 65%), cytokeratin 7 (16 of 26; 62%), GATA3 (16 of 26; 62%), and cytokeratin 5/6 (16 of 26; 62%). STAT-6, CD31, CD34, and HMB45 were all nonreactive, whereas smooth muscle actin often showed at least focal immunoreactivity (22 of 26; 85%). Epithelial-to-mesenchymal transition markers were frequently expressed, including vimentin (26 of 26; 100%), FoxC2 (26 of 26; 100%), SNAIL (23 of 26; 88.5%), and ZEB1 (18 of 26; 69.2%). Follow-up was available for 24 patients (median, 7 months). Sixteen of 28 patients (57%) died of disease (overall mean survival, 9.1 months). The presence of myxoid or chordoid features was associated with reduced survival (P < .05). CONCLUSIONS: -Sarcomatoid UCa is an aggressive form of UCa that frequently expresses epithelial-to-mesenchymal transition markers, suggesting a possible mechanism associated with aggressive tumor behavior.
Authors: Sounak Gupta; Carlos P Sosa; Farhad Kosari; Andrew Folpe; Kaustubh N Bhinge; Lin Yang; Alireza Agahi; Sarah H Johnson; Igor Frank; Stephen A Boorjian; Donna E Hansel; Hikmat A Al-Ahmadie; Victor E Reuter; George Vasmatzis; Rafael E Jimenez; Loren Herrera-Hernandez; John C Cheville Journal: Hum Pathol Date: 2019-04-01 Impact factor: 3.466
Authors: Nima Almassi; Emily A Vertosick; Daniel D Sjoberg; Nathan C Wong; Chun Huang; Eugene J Pietzak; Eugene K Cha; Timothy F Donahue; Guido Dalbagni; Bernard H Bochner; Gopa Iyer; Jonathan E Rosenberg; Dean F Bajorin; Hikmat Al-Ahmadie; Alvin C Goh Journal: BJU Int Date: 2021-05-24 Impact factor: 5.969
Authors: Max Kates; Meera R Chappidi; Aaron Brant; Niv Milbar; Nikolai A Sopko; Christian Meyer; Stephanie A Terezakis; Joseph M Herman; Jonathan E Efron; Bashar Safar; Phuoc T Tran; Nita Ahuja; Phillip M Pierorazio; Trinity J Bivalacqua Journal: Bladder Cancer Date: 2017-07-27
Authors: Joshua J Meeks; Hikmat Al-Ahmadie; Bishoy M Faltas; John A Taylor; Thomas W Flaig; David J DeGraff; Emil Christensen; Benjamin L Woolbright; David J McConkey; Lars Dyrskjøt Journal: Nat Rev Urol Date: 2020-03-31 Impact factor: 14.432